



Press release

LU Bioscience Invests in ProNoxis AB

1 June 2009, Lund, Sweden LU Bioscience AB (LU Bio) today announces that it has made an investment in ProNoxis AB.

ProNoxis is a spin out from Redoxis and is focused around developing anti-inflammatory therapeutics that act through the NADPH oxidase complex (NOX2), an invention based on the research by Prof Rikard Holmdahl and Dr Peter Olofsson.

"We have an intention to focus on this specific mechanism for treatment of autoimmune diseases, and with this investment it is possible for us to develop this promising project further", says CEO of Redoxis, Peter Olofsson.

This is the third investment for the recently formed investment company and the first where LU Bio is the lead investor. Karolinska Development is coinvesting and Redoxis AB is the third owner of ProNoxis.

"We are facing a period of time in our company's life with a number of promising projects and we are ready now to be the lead investor. The investment in ProNoxis is the first lead investment in a coming range of interesting projects", comments CEO of LU Bio, Thomas Andersson.

About ProNoxis AB

ProNoxis develops, produces and markets novel treatments for autoimmune disorders where modification of NADPH oxidase (NOX2) activity is one key for diseases like rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (IBD). ProNoxis is a spin-out from Redoxis.

About LU Bioscience AB

Lund University Bioscience AB (LU Bio) was established to help satisfy the need to transform high-end research results and innovations into attractive business propositions through supporting researchers. LU Bio is an early-stage investor who provides both capital and industrial development expertise to enable a fast and efficient development of bioscience inventions.

www.lubio.se

For more information, please contact

Anki Malmborg Hager, LU Bioscience AB
mobile +46 768 48 28 22, anki@lubio.se